Investors focused on the Medical space have likely heard of Amedisys (AMED - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of AMED and the rest of the Medical group's stocks.
Amedisys is one of 866 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AMED is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for AMED's full-year earnings has moved 0.80% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, AMED has moved about 10.90% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 1.18% on a year-to-date basis. This shows that Amedisys is outperforming its peers so far this year.
Looking more specifically, AMED belongs to the Medical - Outpatient and Home Healthcare industry, which includes 17 individual stocks and currently sits at #27 in the Zacks Industry Rank. On average, stocks in this group have gained 11.58% this year, meaning that AMED is slightly underperforming its industry in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to AMED as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of Amedisys (AMED - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of AMED and the rest of the Medical group's stocks.
Amedisys is one of 866 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AMED is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for AMED's full-year earnings has moved 0.80% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, AMED has moved about 10.90% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 1.18% on a year-to-date basis. This shows that Amedisys is outperforming its peers so far this year.
Looking more specifically, AMED belongs to the Medical - Outpatient and Home Healthcare industry, which includes 17 individual stocks and currently sits at #27 in the Zacks Industry Rank. On average, stocks in this group have gained 11.58% this year, meaning that AMED is slightly underperforming its industry in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to AMED as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on AMED - FREE